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It is not clear if 18FDG-PET can be useful for 
detection of inflammation in low to moderate carotid 
stenosis. We studied 15 patients scheduled for 
endarterectomy with contralateral carotids with less than 
50% stenosis. 18-FDG-PET was performed prior to CEA 
and 3 months following surgery. FDG-uptake values were 
calculated based on maximum standardized uptake value 
(SUV) and corresponding uptake ratios. We confirmed by 
CD68 macrophage staining that FDG accumulation 
corresponds to active inflammation (R=0.8 p<0.005). We 
found significant correlation between the FDG-uptake in 
the carotids scheduled for CEA and contralateral carotids 
with low to moderate stenosis  (R=0.9 p<0.001). The FDG 
uptake ratio in the contralateral arteries remained stable on 
the follow-up imaging (1.15+/-0.2 vs. 1.14+/-0.1; R=0.7 
p=0.006).  We did not find correlation between FDG 
uptake and symptomatic or asymptomatic patients, degree 
of carotid stenosis and vascular risk factors. This is a 
prospective, preliminary in vivo study demonstrating that 
low to moderate carotid atherosclerosis can be detected 
using 18-FDG-PET imaging and highlights the truly 














Atherosclerosis is a diffuse, chronic inflammatory disease 
that involves the vascular, metabolic and immune systems 
and leads to plaque vulnerability. These ruptured or so-
called vulnerable/unstable atherosclerotic lesions are 
responsible for a significant proportion of cerebral ischemic 
strokes (1-2). Patient eligibility for carotid endarterectomy  
(CEA) or angioplasty has been traditionally centered on 
assessing the degree of luminal stenosis (3) and current 
definitions of plaque vulnerability are based on 
morphology and plaque texture estimated by ecodoppler 
imaging, Magnetic Resonance Imaging (MRI) or 
angiography  (4-5). However, it is difficult to clearly define 
whether a plaque is stable or vulnerable by currently 
available techniques, although, in recent years advances in 
MRI have improved our ability to identify carotid plaque 
morphology (6). More recently, vulnerable atherosclerotic 
plaques have been characterized by their expression of high 
numbers of inflammatory cells (7-10) and in vivo imaging 
of the current metabolic, dynamic state of the plaque would 
help to identify those patients at highest risk of ischemic 
stroke  (11-12). In a clinical situation, number of patients 
suffering from stroke or transient ischemic attack (TIA)
18FDG-PET imaging detects early carotid inflammation 
 
Table 1. Subject characteristics  
No of patients, n 15 
Male, n  (%) 11  (73) 
Age 68  (range 53-80) 
Symptomatic carotid disease, n  (%) 10  (67) 
          Stroke, n  (%)  4  (40) 
          TIA1, n  (%) 4  (40) 
          Amaurosis fugax, n  (%) 2  (20) 
Hypertension, n  (%) 11  (73) 
Diabetes, n  (%) 8  (53) 
HbA1c, % 8.11 +/- 0.8 
Fasting glucose prior to PET  (mg/dL) 103 +/- 21 
Hyperlipidemia, n  (%)  11  (73) 
Total cholesterol  (mmol/l) 4.9 +/- 1 
LDL  (mmol/l) 2.8 +/- 0.9 
HDL  (mmol/l) 1.2 +/- 0.2 
TG  (mmol/l) 1.8 +/- 0.9 
ApoA1  (mmol/l) 1.2 +/- 0.3 
ApoB  (mmol/l) 0.8 +/- 0.9 
Smoker or exsmoker, n  (%) 9  (60) 
Coronary artery disease, n  (%) 6  (40) 
Peripheral vasculopathy, n  (%) 4  (27) 
History of stroke, n  (%) 7  (47) 
Antiplatelet therapy before CEA2, n  (%) 9  (60) 
RAS-b3 therapy before CEA, n  (%) 7  (47) 
Statins therapy before CEA, n  (%) 7  (47) 
Antiplatelet therapy after CEA, n  (%) 15  (100) 
RAS-b therapy after CEA, n  (%) 7  (47) 
Statins therapy after CEA, n  (%) 11  (73) 
Abbreviations: 1Transient Ischemic Attack, 2Carotid Endarterectomy, 3Renin Angiotensine System-blockers 
 
present low-to-moderate carotid stenosis without other clear 
cause of their vascular event either cardiac or intracranial. 
Thus, studies of carotid wall with low-to-moderate stenosis 
due to atherosclerosis and identification of local foci of 
inflammation or increased risk of thrombosis may be very 
relevant.  
 
Fluorine-18 fluorodeoxyglucose (18-FDG) 
accumulates in inflamed tissues and several groups have 
established that inflamed blood vessels and atherosclerotic 
lesions have increased uptake of 18-FDG (13-14). More 
recently, 18FDG uptake was shown to be greater in carotid 
plaques obtained from patients with clinical evidence of 
carotid plaque instability (15-16) and macrophage infiltration 
(17). This 18-FDG enhancement has been also demonstrated in 
animal models of atherosclerosis (18) and verified in human 
studies of patients with Takayasu’s arteritis, giant cell arteritis, 
polymyalgia rheumatica and non-specific aortitis (19-21). 
Furthermore, recent studies have demonstrated the 
reproducibility of the studies with positron emission 
tomography (PET) Imaging (22) and changes in vascular FDG 
activity can be identified by repeat PET/CT imaging (23). As 
FDG uptake is transient and present only at the time of active 
inflammation, it may offer a powerful tool to provide early 
detection of inflammatory foci within the carotid artery. In this 
work we have examined the 18-FDG abnormal uptake in the 
contralateral carotid artery at larger than previously reported 
(22) two time-points in patients undergoing CEA with low-to-
moderate grade contralateral stenosis (<50%).  
 
3. MATERIALS AND METHODS 
 
3.1. Patient recruitment  
We studied prospectively, 15 patients with 
internal carotid artery stenosis with indication for CEA (3, 
5). We included asymptomatic patients and patients with 
history of recent stroke or TIA  (<6 months) (Table 1). In 
each patient the diagnosis of carotid stenosis was made by 
duplex and confirmed by angio-MRI or X-ray angiography. 
All patients were seen by a stroke specialist. Every patient 
underwent laboratory studies, cranial and carotid MRI, and 
18-FDG-PET before and after CEA (mean time of 101+/-
10 days). One patient refused post CEA study.  Patients 
were excluded if they had significant contralateral carotid 
stenosis (>50%) or contraindications to MRI or PET 
imaging. The study was approved by the hospital ethics 
committee. All the patients gave written informed consent. 
 
3.2. FDG-PET and CT brain scans 
All patients received an integrated FDG-PET/CT using a 
Discovery ST scanner (General Electric Healthcare). All 
patients were normoglycemic at the time of the FDG-PET 
scan with non-diabetic patients harvesting all night, with 
the FDG-PET scan carried out in the morning and diabetic 
patients, harvesting 6h after taking their usual treatment, 
and having their glycemia corrected with insulin if 
necessary prior to PET scan  (mean glycemia prior to PET 
was 103+/-21 mg/dL, Table 1). PET was performed with 
3.71 mm slice thickness with 5 overlapping slices in 3D 
mode including brain and neck structures (two beds). A 
stiff cervical collar was worn to minimize patient 
movement. Approximately 370 MBq of FDG was 
administered intravenously as a bolus in a dark and quiet 
room, and static emission images were obtained 30-45 min 
later. Attenuation correction 4-slice CT helical scans 
(CTAC) were obtained at 3.71mm slice-thickness, 120 KV 
tube voltage and 60 mA tube current. PET images were 
reconstructed using the 3D iterative algorithm with Fourier 
rebinning and attenuation-weighted ordered subsets-
expectation maximization (32 subsets; 5 iterations). PET
18FDG-PET imaging detects early carotid inflammation 
 
Table 2. Positron Emission Tomography  (PET) quantification data in studied subjects 
Patien
t 
















18FDG uptake ratio  
(ipsilateral carotid) 
18FDG uptake ratio  
(contralateral carotid) 
18FDG uptake ratio  
(control PET, 
contralateral carotid) 
1 M1 53 Stroke 37 days 25 121 1.17 1.15 1.13 
2 M 59 Stroke 7 days 0 99 0.97 0.98 1.06 
3 F2 67 Asymptomatic - 12 111 1.04 1.10 1.00 
4 M 60 Asymptomatic-
TIA4 disartria 
- 40 143 1.3 1.09 1.15 
5 M 73 TIA 28 days 3 101 1.33 1.11 1.09 
6 M 66 Amaurosis 16 days 
 
7 110 1.20 1.03 1.11 
7 M 72 Amaurosis 40 days 20 110 1.23 1.30 1.35 
8 M 64 Asymptomatic - 5 103 1.10 1.02 1.10 
9 M 80 Stroke 20 days 4 96 0.91 0.88 0.95 
10 M 59 Asymptomatic - 45 - 1.37 1.35 - 
11 M 65 TIA 14 days 9 126 1.76 1.65 1.26 
12 F 77 TIA 76 days 48 175 1.13 1.12 1.50 
13 F 76 TIA 53 days 3 91 1.15 1.20 1.08 
14 M 80 Asymptomatic-
Stroke 
270 days 21 134 1.22 1.17 1.10 
15 F 70 TIA 114 days 11 110 1.09 1.07 1.01 
Time from symptoms to PET scan: 41.5  (7-114); Time from PET scan to CEA: 16.9  (0-48); Time from first to second PET 
scan: 116+/-22. Data presented for the ipsilateral carotid indicates the carotid scheduled for carotid endarterectomy (CEA), 
contralateral carotid is the carotid contralateral to the one scheduled for CEA, the control PET  (second PET) is 18-FDG uptake 
ratio in the contralateral carotid on follow-up. 1male, 2female, 3carotid endarterectomy, 4Transient Ischemic Attack. 
 
and CT images were automatically fused by use of 
automatic image registration software. Carotid plaque exact 
localization was later confirmed by angio-MRI. 
 
3.3. Study interpretation and analysis 
Two speciality-trained persons blinded to patient 
characteristics (age, sex, symptomatic or asymptomatic 
disease, vascular risk factors and treatment) jointly 
reviewed the FDG-PET/CT scans and confirmed plaque 
localization by angioRMI. A semi-quantitative 
assessment of FDG uptake was carried out for each 
patient. Two-centimetre circular regions of interest 
(ROI) were drawn on CT images around the area 
including carotids in each slice, and then transferred 
onto the corresponding co-registered PET image to 
enable FDG uptake values based on maximum 
standardized uptake value, known as target-to-
background ratio (SUVmax in mg/dL). The analysis 
included a vascular region 56mm over and below the 
level of the carotid bifurcation, and slice-activity curves 
at 3mm intervals were calculated in order to visualize 
plaque and basal metabolism (details in Figures 3B, 4C). 
The uptake for each plaque was divided by the average 
of the normal vessel wall values to give an uptake ratio. 
This was done in order to normalize for interpatient 
variations in FDG delivery to the plaque and basal 
metaboilsm. The obtained ratio value was used for 
statistical analysis (Table 2).  
3.4. Carotid specimens/histology/immunohistochemistry 
Carotid specimens were excised by the vascular 
surgeon without damage to the luminal surface. They were 
immediately rinsed in 0.9% saline, snap frozen in liquid 
nitrogen, stored at -80ºC, and later processed for histology. 
Specimens were transversely sectioned at 3-mm intervals. 
Plaque morphology was assessed immediately after surgery 
and later by examination of the anatomo-pathology of 
haematoxylin and eosin stained sections. The peroxidase 
method was used for immunohistochemical staining 
(Vectastain kit, Vector). After blocking endogenous 
peroxidase, the sections were incubated with normal serum 
and then incubated at 4ºC overnight with the primary 
monoclonal anti-CD68 antibody (1:100). Afterwards, 
sections were incubated for 1 hour with secondary antibody  
(1:200) at room temperature. The peroxidase reaction was 
visualised with 0.05% diaminobenzidine. Negative controls 
in which the primary antibody was replaced with PBS were 
used to test for non-specific binding (data not included). 
Computer–assisted planimetry was used to quantify areas 
of staining as described previously (18, 24). The sections 
were computerized as colour-encoded digitized images 
(Nikon DS-2Mv camera, DS-U2 image processing unit and 
analysing software NIKON NIS-Elements vs. 3.21). Each 
section was transformed to a binary image with the same 
defined threshold for all studied sections. Total section 
areas and areas of macrophage infiltration (CD68 positive) 
were outlined manually by comparing the computerized




Figure 1. The mean area fraction covered by CD68+ 
inflammatory cells correlated with the degree of FDG 





Figure 2. 18FDG-uptake ratio in the ipsilateral carotid 
correlated with 18FDG-uptake ratio in the contralateral 
asymptomatic Carotid with low-to-moderate grade of 
stenosis  (R=0.9  p<0.001).  
 
image with images at 4x and 20x magnification. Areas of 
macrophage infiltration were recorded as an absolute area 
of staining in each slice (mm2). Additionally, inflammation 
(area fraction) was recorded as a percentage of CD68 
staining. This was done in order to validate the PET FDG 
uptake correspondence with macrophage infiltrates.  
 
3.5. Statistical methods 
Clinical data, different treatments and net 18-
FDG accumulation rates were tested for normal distribution 
with K-S statistics. Correlation coefficients were assessed 
with Pearson or Spearman rank correlation tests for FDG 
uptake in the ipsilateral carotid, and contralateral areas, 
before and 3 months after CEA. Student’s t test and 
Pearson correlation was used for normally distributed data. 
If data was not normally distributed we used non-
parametric statistics, Spearman rank test for paired 
samples, and Mann-Whitney U tests for unpaired samples. 
The analyses were 2-tailed unless otherwise specified. 
Statistical significance was established at a P value of 
<0.05. Correlation was significant at a P value of <0.01. 
4. RESULTS  
 
Clinical details of the 15 patients are summarized 
in Table 1. We included 11 men and 4 women, aged 68 
(range 53-80). 10 patients had symptomatic carotid artery 
disease: 3 of the patients had suffered a prior ischemic 
stroke (PACI, superficial ACM; PACI, Deep ACM; PACI, 
corona radiata, respectively according to TOAST 
classification (25)), 4 had TIA with symptoms 
corresponding to the carotid scheduled for CEA, 2 had 
suffered amaurosis fugax and 1 patient had suffered a TIA, 
referring also with a previous amaurosis fugax. The 
remaining 5 patients were asymptomatic: 1 patient suffered 
a stroke (LACI) more than six months before CEA, 1 
suffered a stroke in the vertebrobasilar territory, 1 had a 
referred transitory episode of dysartria which prevented 
localization of the territory and 2 had no symptoms at all. 
All patients had risk factors consistent with severe 
atherosclerotic disease. Duplex findings were confirmed in 
14 patients by angio-MRI and 1 patient by angio-MRI and 
X-ray angiography. Angio-MRI showed that significant 
stenosis was >90% in 8 patients, >80% in 4 patients and 
>70% in 3 patients. The contralateral carotid showed <25% 
stenosis in 9 patients and 25-50% in 6 patients. The mean 
time from the first PET scan to second one was 116+/-22 
days. The mean time from CEA to the second PET scan 
was 101+/-10 days. 
 
4.1. FDG ipsilateral uptake and plaque inflammation 
To confirm that in our population 18FDG-PET 
tracks inflammation in the plaque, we quantified the mean 
area fraction covered by CD68+ inflammatory cells and we 
expressed it as a percentage of total plaque area (7.9%, 
range 1-18). We found a statistically significant correlation 
between the degree of FDG accumulation and the presence 
of macrophages in the atherosclerotic plaques (R=0.8, 
p<0.005) (Figure.1). This allows us to assume that 
contralateral carotid 18FDG-uptake corresponds to active 
inflammation.  
 
There was no correlation between FDG uptake 
and the following variables: time from symptoms to PET 
imaging, symptomatic  (as defined by NASCET criteria (4), 
or recently symptomatic patients and asymptomatic 
patients, degree of carotid stenosis, age, gender, hs-CRP, 
blood pressure, serum lipids (total cholesterol, LDL-c, 
HDL-c, triglycerides), smoking, history of coronary artery 
disease, peripheral vasculopathy or prior stroke and 
treatment.  
 
4.2. FDG uptakes in ipsi- and contralateral carotid 
arteries 
We found a statistically significant correlation 
between the degree of FDG accumulation in the ipsilateral 
carotids scheduled for CEA and contralateral asymptomatic 
carotids with low-to-moderate stenosis (R=0.9 p<0.001, 
Figure 2). The FDG uptake rates in the contralateral arteries 
remained stable on second exploration (1.15+/-0.2 vs. 
1.14+/-0.1; R=0.7 p=0.006) with a global reduction in 18-
FDG accumulation of 1.3% but without significant 
difference between the two PET explorations  (p=0.97)  
(Table 2, Figure 3). Patients on treatment with statins




Figure 3. The 18FDG-uptake rates in the contralateral 
arteries remained stable on second exploration  (1.15+/-0.2 
vs. 1.14+/-0.1; R=0.7 p=0.006, PET 1 vs. PET 2, 
respectively) with a global reduction in 18FDG 
accumulation of 1.3% but without significant difference 
between the two PET explorations. 
 
showed a tendency to present a more pronounced decrease 
in FDG uptake on second PET (p=0.05). Figures 4, 5 A to 
C, represent CT and 18FDG-PET fused images and 
corresponding slice-activity curves calculated in order to 
represent 18FDG-uptakes. Each point corresponds to 





  In this prospective study we examined the 
association of bilateral carotid disease with plaque 
metabolic activity in patients with low-to-moderate 
asymptomatic contralateral stenosis. In our series, patients 
scheduled for CEA had a notable inflammatory response in 
the contralateral carotid that could be tracked by 18FDG-
PET imaging. There was an important correlation in 
18FDG accumulation between ipsi- and contralateral 
carotids. As has been recently reported (15, 17-18, 26), we 
have found a significant correlation between ipsilateral 
FDG uptake and cellular inflammatory response in the 
carotid plaque. The contralateral FDG uptake, if present, 
would therefore probably be associated with macrophage 
inflammatory foci in the asymptomatic artery. Importantly, 
contralateral 18FDG-uptake remained stable after 3 
months. This may expand the 14 days window recently 
suggested by Rudd et al  (27), at least, for carotids with 
low-to-moderate stenosis.  
 
 A recent study established that FDG-PET 
imaging could be used to assess the severity of 
inflammation in human carotid plaques (17). The authors 
found a significant correlation between the PET signal from 
carotid plaques and macrophage staining from the 
corresponding histology sections. This correlation was even 
stronger when they compared mean FDG uptake with mean 
percentage CD68 staining, as we have used in our study. 
FDG uptake did not correlate with plaque area, thickness or 
area of smooth muscle cell staining. Additionaly, in animal 
models, macrophage density, assessed by histology, 
correlated with non-invasive PET measurements of FDG 
uptake in rabbit atherosclerotic aortas. FDG uptake did not 
correlate with either aortic wall thickness or smooth muscle 
cell staining of the specimens (18, 26). Our study confirms 
that in our hospital-based population carotid 18FDG-uptake 
corresponds to inflammation in the plaque. 
 
All previous studies using 18FDG-PET included 
only recent symptomatic patients with high-grade carotid 
stenosis or were retrospective studies in patients with 
cancer (28). In our study we have included symptomatic 
and asymptomatic patients. The symptomatic patients could 
be recent (<1 month) or not. Studies using 18FDG-PET and 
high resolution MRI suggest that we could identify the 
culprit lesion responsible for a cerebrovascular event by 
18FDG PET  (16). Authors reported 12 patients with recent 
TIA, 10 exhibited high FDG uptake, in 7 the uptake was 
seen in the lesion targeted for CEA. Two other patients 
showed inflamed non-stenotic lesions located in the same 
vascular territory and one, a lesion in the vertebral artery 
which could also explain the symptomatology. 
Contralateral asymptomatic plaques demonstrated 
inflammation but not to the extent of the symptomatic side. 
Our study, although preliminary, suggests that 18FDG-PET 
may detect not only recently symptomatic, aggressive 
plaques, but also any active, inflammatory lesion 
independently on the grade of stenosis or symptomatology 
(8). Results are in agreement with previous published 
studies on anatomo-pathological findings in symptomatic 
and asymptomatic patients. Both plaques with high and 
moderate degree stenosis demonstrate features of 
inflammation and thrombosis (29). Our study further 
confirms, that inflammation is truly systemic. 
Disappointingly, it seems difficult to assume that PET will 
be able to identify only the culprit lesions. We did not find 
correlation between FDG uptake and other vascular risk 
factors, although the small number of patients included in 
the study is an important limitation to find statistically 
significant differences. 
 
In our series, the contralateral carotid stenosis 
was low or moderate i.e. ≤ 50% in all patients, and there 
was an important correlation in FDG-uptake with carotids 
scheduled for CEA. This suggests, that if plaque 
vulnerability is measured by the inflammatory response, it 
is independent from the grade of stenosis. Similar results 
were also reported in a study performed by Tang et al. (30) 
using a different technique of high-resolution ultrasmall 
superparamagnetic iron-oxide (USPIO) enhanced MRI in 
20 patients with symptomatic carotid stenosis scheduled for 
CEA. USPIO is taken up by activated macrophages and 
allows the direct visualization of macrophage infiltration of 
carotid atheroma in vivo (31). Despite a mean carotid 
stenosis of 46%, 95% of asymptomatic plaques 
demonstrated USPIO uptake, suggesting a bilateral, 
inflammatory burden within their carotid atheromas. We 
know from studies of coronary arteries that plaque rupture 
occurs at low degrees of narrowing and the degree of 
narrowing poorly predicts clinical events  (32). 
Approximately 40% to 50% of coronary rupture sites show 
<50% diameter stenosis  (33), and the same may be true in 




Figure 4. A. High resolution CT, 18FDG PET and fused images; coronal, sagital and transaxial slices taken from patient number 
11, a man of 65 years, with dyslipidemia treated with statins and family history of coronary artery disease, diagnosed with left 
carotid territory stroke who was referred for  aphasia and right hemiparesia and several left amaurosis fugax episodes during the 
last three months. Ecodoppler and angio-MRI showed calcified diffuse plaques with preocclusive left internal carotid stenosis, 
50% right internal carotid stenosis and occlusion of right vertebral artery. CT demonstrated several calcified areas  (red arrows). 
PET showed high 18FDG uptake areas on both carotid arteries  (yellow arrows). B. Slice-activity curves were calculated in order 
to represent 18FDG-uptakes. Each point corresponds to individual uptake in the studied slice  (at an interval of 3mm). Points 1 to 
14 correspond to internal carotid artery. Point 15 corresponds to carotid bifurcation. Points 16 to 30 correspond to the common 
carotid artery. Slice-activity curves show an increased FDG uptake ratio at the internal carotid artery and bifurcation on both 




Figure 5. A. High resolution CT, 18FDG PET and fused images; transaxial slices taken from patient number 7, a 72 year 
old man with history of hypertension, diabetes and dyslipidemia taking aspirin, RAS-b and statins, who suffered a right 
amaurosis fugax. AngioMRI showed a 90% right stenosis and 25% left stenosis in carotid bifurcation. Yellow arrow 
highlights FDG uptake in the left internal carotid artery before (A) and after (B) CEA. C. In this patient there was 
increased 18FDG-uptake in the bifurcation area of the contralateral carotid to the one scheduled for CEA (ratio 1.30). 
18FDG-uptake remained stable on second exploration (ratio 1.35).   
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carotid disease (34). It has recently been shown that risk 
of plaque rupture, and, therefore, risk of a downstream 
embolic event, is determined more by plaque 
composition than plaque size or degree of stenosis  (35). 
But neither the ACST nor ACAS trials were able to 
determine whether asymptomatic patients with 50 to 
69% stenosis would benefit from surgical intervention 
or more aggressive medical treatment  (36). Therefore, 
the role of surveillance of the contralateral carotid artery 
remains unclear. A prospective study correlating future 
ischemic events with inflammatory plaque activity will 
be necessary to confirm this hypothesis. In our series, 
the contralateral carotids remained asymptomatic, 
although, patients were not screened for silent infarcts at 
3 months.  
 
In our consecutive PET scans, the same pattern 
of uptake seen in the first study appears in the second 
one at mean time of over 3 months. Only two patients 
showed a decrease in FDG uptake and one patient 
showed high FDG-uptake in a plaque that was 
previously silent. Rudd et al (22, 27) tested the near-
term reproducibility of 18FDG PET imaging of 
atherosclerosis in 11 and 19 patients with FDG-PET/TC 
twice, 14 days apart and assessed interobserver and 
intraobserver agreement and interscan variability 
concluding spontaneous change in plaque FDG uptake is 
low and 18FDG PET is highly reproducible. 
 
Patients on treatment with statins showed a 
tendency to present a more pronounced decrease in FDG 
uptake on second PET  (p=0.05), Only seven patients 
were on statins before they presented with stroke 
symptoms or they PET scans were performed. Following 
PET-imaging, 4 patients did not receive statins, one was 
an asymptomatic patient with normal lipidic profile, one 
was a symptomatic patient with LDL levels of 
1.5mmol/L and 2 patients withdraw the treatment. 
However, the heterogeneity of doses and timing prompts 
to perform further studies to confirm this tendency. 
 
We believe there is a need for new adjuncts to 
risk-stratify patients. Patient symptomatology and 
degree of luminal narrowing, which have been 
previously used as clinical grounds for surgical 
intervention, could be no longer appropriate to be 
considered solely for decision making. The finding of 
corresponding activity in the contralateral plaque is a 
finding that highlights the truly systemic nature of 
vulnerable and inflammatory atheroma. One of the 
limitations of the study is that it is a hospital-based 
cohort of patients with both symptomatic and 
asymptomatic carotid disease. Truly asymptomatic 
patients would certainly be an interesting group for 
future PET studies with MRI assessement of new silent 
brain lesions and follow-up study of any cardiovascular 
events. New studies should confirm the effect of statins 
on plaque inflammatory activity. Whether identification 
of an inflammatory phase in atherosclerotic carotid 
disease with PET will help in stratify risk and patient 
selection for more detailed cardiovascluar risk screening 
and early treatment will require further studies.  
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